Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 4Phase 1/2 3Phase 2/3 1Phase 1 1

Status

Active not recruiting 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 3Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 9Small Cell Lung Carcinoma 7Biliary Tract Neoplasms 7Carcinoma, Hepatocellular 6Urinary Bladder Neoplasms 4Liver Neoplasms 4Carcinoma 4Neoplasm Metastasis 3Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma Extensive Disease 2Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Non-Muscle Invasive Bladder Neoplasms 2Gallbladder Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Urothelial Cancer 1Sarcoma 1Radiation Pneumonitis 1Pancoast Syndrome 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Non Small Cell Lung Carcinoma NSCLC 1Non Small Cell Lung Cancer NSCLC 1Non - Small Cell Lung Cancer NSCLC 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1

Interventions

Carboplatin 17Cisplatin 14Paclitaxel 12Pemetrexed 11pembrolizumab 9Gemcitabine 7Docetaxel 6Sorafenib 5osimertinib 4durvalumab 4130-nm albumin-bound paclitaxel 4padeliporfin 3cabozantinib 3atezolizumab 3Taxes 3Radiotherapy 3Mitomycin 3Magnetic Resonance Spectroscopy 3Cetuximab 3Bevacizumab 31-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3trifluridine tipiracil drug combination 2regorafenib 2olaparib 2Sunitinib 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2Radiation 2Nivolumab 2Irinotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma × durvalumab × Clear all
NCT05043090 2026-05-22

SAMETA

AstraZeneca

Phase 3 Active not recruiting
148 enrolled
Genitourinary

Carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT03703297 2025-11-21

ADRIATIC

AstraZeneca

Phase 3 Active not recruiting
730 enrolled 19 charts 1 FDA
Thoracic

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03519971 2025-10-28

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

AstraZeneca

Phase 3 Active not recruiting
328 enrolled 23 charts
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03800134 2025-06-11

AEGEAN

AstraZeneca

Phase 3 Active not recruiting
825 enrolled 1 FDA
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡